Cancer institute, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China (mainland).
Department of Medical Oncology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China (mainland).
Med Sci Monit. 2021 Feb 14;27:e929104. doi: 10.12659/MSM.929104.
BACKGROUND Gastric cancer (GC) is one of the leading causes of cancer-related mortality worldwide. We aimed to identify differentially expressed genes (DEGs) and their potential mechanisms associated with the prognosis of GC patients. MATERIAL AND METHODS This study was based on gene profiling information for 37 paired samples of GC and adjacent normal tissues from the GSE118916, GSE79973, and GSE19826 datasets in the Gene Expression Omnibus database. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were used to investigate the biological role of the DEGs. The protein-protein interaction (PPI) network was constructed by Cytoscape, and the Kaplan-Meier plotter was used for prognostic analysis. RESULTS We identified 119 DEGs, including 21 upregulated and 98 downregulated genes, in GC. The 21 upregulated genes were mainly enriched in extracellular matrix-receptor interaction, focal adhesion, and transforming growth factor-ß signaling, while the 98 downregulated genes were significantly associated with gastric acid secretion, retinol metabolism, and metabolism of xenobiotics by cytochrome P450. Thirty hub DEGs were obtained for further analysis. Twenty-five of the 30 hub DEGs were significantly associated with the prognosis of GC, and 21 of the 25 hub DEGs showed consistent expression trends within the 3 profile datasets. KEGG reanalysis of these 21 hub DEGs showed that COL1A1, COL1A2, COL2A1, COL11A1, THBS2, and SPP1 were mainly enriched in the extracellular matrix-receptor interaction pathways. CONCLUSIONS We identified 6 genes that were significantly related to the prognosis of GC patients. These genes and pathways could serve as potential prognostic markers and be used to develop treatments for GC patients.
胃癌(GC)是全球癌症相关死亡的主要原因之一。我们旨在确定与 GC 患者预后相关的差异表达基因(DEG)及其潜在机制。
本研究基于基因表达谱信息,从 GEO 数据库中选择了 37 对 GC 及相邻正常组织的样本(GSE118916、GSE79973 和 GSE19826)。使用基因本体论和京都基因与基因组百科全书(KEGG)分析来研究 DEG 的生物学作用。通过 Cytoscape 构建蛋白质-蛋白质相互作用(PPI)网络,并用 Kaplan-Meier plotter 进行预后分析。
我们鉴定出 119 个 DEG,包括 21 个上调基因和 98 个下调基因。21 个上调基因主要富集在外源基质-受体相互作用、焦点粘连和转化生长因子-β信号转导途径,而 98 个下调基因则与胃酸分泌、视黄醇代谢和细胞色素 P450 代谢外源化合物显著相关。进一步分析获得了 30 个关键 DEG。30 个关键 DEG 中有 25 个与 GC 的预后显著相关,其中 25 个关键 DEG 中有 21 个在 3 个数据集的表达趋势一致。对这 21 个关键 DEG 的 KEGG 重新分析表明,COL1A1、COL1A2、COL2A1、COL11A1、THBS2 和 SPP1 主要富集在外源基质-受体相互作用途径中。
我们鉴定出 6 个与 GC 患者预后显著相关的基因。这些基因和途径可能成为潜在的预后标志物,并可用于开发 GC 患者的治疗方法。